Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2011

View Archived Issues

Clinical data presented on several AstraZeneca products in solid tumors

Boehringer Ingelheim claims new HCV serine protease NS3 inhibitors

Z-123212 reverses symptoms of neuropathic pain by state-dependent inhibition of ion channels

Galderma presents new matrix metalloproteinase inhibitors for rosacea

Scientists at GSK disclose novel fatty acid synthase inhibitors

Final data presented from phase I trial of X-Excite versus Viagra

Phase II trial assesses second-line danusertib in metastatic castration-resistant prostate cancer

Interim first-in-human data support safety/activity of INCB-028060 in advanced solid tumors

Combination of lorvotuzumab mertansine, dexamethasone and lenalidomide is safe in multiple myeloma

Belatacept remains superior to ciclosporin after 3 years of treatment in BENEFIT trial

New dUPTase inhibitors for cancer prepared at Taiho

Daiichi Sankyo patents novel renin inhibitors

GSK begins phase II GSK-2251052 trials in urinary tract and intra-abdominal infections

Rectiv approved in U.S. for pain associated with chronic anal fissures

RG-3039 receives FDA fast track status for spinal muscular atrophy

Meda files MAA with EMA for Zyclara

Naurex begins phase II trial of novel antidepressant GLYX-13

Tobira Therapeutics begins phase IIb cenicriviroc trial in HIV infection

Rexahn Pharmaceuticals completes enrollment in phase IIb Serdaxin trial

FDA committee votes against approval of canakinumab in gouty arthritis

CHMP recommends approval of linagliptin for type 2 diabetes

EMA accepts for review Eisai's perampanel MAA for partial-onset seizures

New phase Ib study to assess TMC-649128 in genotype 1 hepatitis C

EMA accepts Adcetris MAA in Hodgkin's and systemic anaplastic large cell lymphoma

FDA issues complete response letter on Remoxy

E.U. approval recommended for Votubia in TSC-associated subependymal giant cell astrocytoma